possible scenarios. CONCLUSIONS: Conjoint analysis can be used to assess the preferences of patients with schizophrenia, and such preferences appear valid and relatively consistent. Although further validation and refinement is needed, our results indicate that conjoint analysis is a feasible and beneficial method for measuring patient preferences among patients with schizophrenia.
PMH40 PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER 2-YEAR ASSESSMENT OF IMPACT ON QUALITY OF LIFE AND CLINICAL SEVERITY: RESULTS FROM ADORE STUDY IN FRANCE
Le Heuzey MF 1 , Tcherny-Lessenot S 2 , Raimond C 2 1 Robert Debre Hospital, Paris, France, 2 Lilly France, Suresnes, France OBJECTIVES: To present 2-year results on treatments prescribed and their impact on quality of life (QoL) and clinical severity of children with Attention Deficit / Hyperactivity Disorder (ADHD). METHODS: ADORE is a 2-year, prospective, international observational study in ADHD. Treatments were classified as pharmacotherapy, psychotherapy, pharmacotherapy and psychotherapy combination, other, and none. As patients were allowed to change treatment, different patients may be included in each group at different endpoints. QoL was measured with the Child Health and Illness Profile (CHIP-CE). Clinical ADHD outcomes were measured with ADHD-Rating scale parent version (ADHD-RS), CGISeverity scale, Children's Global Assessment Scale (CGAS) and Strengths and Difficulties Questionnaire (SDQ). Changes in outcomes presented hereafter were estimated on all patients followed 2 years and having at least baseline and 24 months visits. RESULTS: Among 255 French patients eligible for analysis, mean age (SD) 8.8 years (2.3), 87.5% male, 137 (53.7%) were followed over 24 months. Treatments were respectively at baseline and 2 years: pharmacotherapy 23.0% & 29.1%, combination pharmacotherapy/psychotherapy 36.6% & 47.0%, psychotherapy 27.2% & 12.7%, other treatment 4.7% & 3.0% and none 8.5% & 8.2%. Between baseline and 2 years, CHIP-CE quality of life improved: mean change from baseline was +5.7 (12.9) for satisfaction, +8.6 (11.8) for achievement, +13.4 (13.0) for risk avoidance, +5.2 (12.4) for resilience and +5.2 (9.6) for comfort. Between baseline and 2 years, mean ADHD-RS change was -18.3 (9.9) leading to a final score of 21.4 (10.7) at 2 years. CGAS mean change was +15.8 (15.5) leading to a final score of 67.1 (16.2). Mean CGI-S change was -1.5 (1.4) leading to a final score of 3.2 (1.3). Rate of patients with 3 1 comorbidity decreased from 76.5% to 54.0% and severity of comorbidities also decreased. CONCLUSIONS: After 2 years, French patients suffering from ADHD symptoms enrolled in this study benefited from improvement of QoL and clinical severity. Interpretation is difficult due to patients changing treatments over the study.
PMH41 SAD BLUE DEPRESSED DAYS, HEALTH-RELATED QUALITY OF LIFE, AND HEALTH BEHAVIORS AMONG WOMEN IN A UNIVERSITY COMMUNITY
Bastardo YM Central University of Venezuela, Caracas, Venezuela OBJECTIVES: To explore the association between Sad Blue Depressed Days (SBDD), health-related quality of life, and health behaviors among women in a university community in Venezuela. METHODS: A random sample of 71 women ranging in age from 18 to 72 years was surveyed using a written questionnaire. The questionnaire included the SBDD question from the Behavioral Risk Factor Surveillance System (BRFSS) and the SF-36 Health Survey. The associations among SBDD, SF-36, demographics, and health behaviors were estimated computing Pearson correlation coefficients for continuous variables and Kendall's tau for categorical variables. RESULTS: The sample had a mean age of 31.98 years (s.d.13.86). The prevalence of alcohol consumption during the previous month was 63.4% and for smoking it was 16.9%. About 60% of the sample reported no exercising regularly during the previous month. 
